Accession Number: | 0001415889-21-004513 |
Date: | 2021-09-20 |
Issuer: | OLEMA PHARMACEUTICALS, INC. (OLMA) |
Original Submission Date: |
HARMON CYRUS
C/O OLEMA PHARMACEUTICALS, INC.
512 2ND STREET, 4TH FLOOR
SAN FRANCISCO, CA 94107
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-09-20 | S | 12,000 | d | $26.30 | 1,063,546 | direct | ||
COMMON STOCK | 2021-09-20 | 0 | $0.00 | 122,028 | indirect | f3 |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | the sales reported in this form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. |
f2 | the weighted average sale price for the transaction reported was $26.30, and the range of prices were between $25.95 and $26.70. upon request from the sec staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
f3 | the shares are held by the harmon family investors llc, of which the reporting person is the manager. |